Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
Kairos Pharma Ltd (AMEX: KAPA) closed the day trading at $0.47 down -5.87% from the previous closing price of $0.50. In other words, the price has decreased by -$5.87 from its previous closing price. On the day, 0.81 million shares were traded.
Ratios:
For a better understanding of KAPA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.52 and its Current Ratio is at 7.52. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 25 ’24 when Murali Ramachandran bought 200 shares for $1.59 per share. The transaction valued at 318 led to the insider holds 133,057 shares of the business.
Samuelson Doug bought 2,500 shares of KAPA for $3,750 on Nov 22 ’24. The Chief Financial Officer now owns 60,796 shares after completing the transaction at $1.50 per share. On Nov 20 ’24, another insider, Yu John S, who serves as the CEO and Chairman of the company, bought 4,000 shares for $1.44 each. As a result, the insider paid 5,760 and bolstered with 5,341,837 shares of the company.
Stock Price History:
Over the past 52 weeks, KAPA has reached a high of $4.00, while it has fallen to a 52-week low of $0.40. The 50-Day Moving Average of the stock is -39.23%, while the 200-Day Moving Average is calculated to be -63.14%.
Shares Statistics:
A total of 15.83M shares are outstanding, with a floating share count of 7.12M. Insiders hold about 57.73% of the company’s shares, while institutions hold 9.36% stake in the company.
Earnings Estimates
A detailed examination of Kairos Pharma Ltd (KAPA) is currently in progress, with 1 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.05 and low estimates of -$0.05.
Analysts are recommending an EPS of between -$0.19 and -$0.19 for the fiscal current year, implying an average EPS of -$0.19. EPS for the following year is -$0.4, with 1.0 analysts recommending between -$0.4 and -$0.4.
